COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
Las Vega (Nevada), United States //— “Chronic Hepatitis B Virus Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Chronic Hepatitis B Virus Market.
The Chronic Hepatitis B Virus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 55+ pipeline drugs in the Chronic Hepatitis B Virus therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
Chronic Hepatitis B Virus Pipeline Analysis
The report provides insights into:
– The report provides detailed insights about emerging therapies for the treatment of Chronic Hepatitis B Virus and the aggregate therapies developed by major pharma companies.
– It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Hepatitis B Virus Treatment.
– It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
– The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
– It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Chronic Hepatitis B Virus market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Route of Administration
Chronic Hepatitis B Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as –
– Oral
– Parenteral
– Intravenous
– Subcutaneous
– Topical
Molecule Type
Products have been categorized under various Molecule types, such as
– Monoclonal Antibody
– Peptides
– Polymer
– Small molecule
– Gene therapy
Delveinsight’s Report Covers Emerging Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage products (Phase I/II and Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
Mechanism of Action (MOA) for the Emerging Pipeline Therapies
– Gene modulators
– Toll-like receptor 8 agonists
– Toll-like receptor 7 agonists
– RNA interference
– Virus internalization inhibitors
– Hepatitis B virus replication inhibitors
Chronic Hepatitis B Virus Therapeutics Landscape
There are approx. 50+ key companies are developing therapies for Chronic Hepatitis B Virus Infection. Currently, Ligand Pharmaceuticals is leading the therapeutics market with its Chronic Hepatitis B Virus Infection drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Chronic Hepatitis B Virus Therapeutics Market include:
Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm, and many others
Chronic Hepatitis B Virus Therapies covered in the report include:
– Pradefovir: Ligand Pharmaceuticals
– RG6346: Dicerna Pharmaceuticals
– PBGENE-HBV: Precision Biosciences
– SBT8230: Silverback Therapeutics
– VIR-3434: Vir Biotechnology
– RG6346:Dicerna Pharmaceuticals
– RG7854: Roche
And many more
Explore More About the Emerging Drugs and Key Companies: Chronic Hepatitis B Virus Pipeline Development Activities
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Chronic Hepatitis B Virus Current Treatment Patterns
4. Chronic Hepatitis B Virus – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Chronic Hepatitis B Virus Late-Stage Products (Phase-III)
7. Chronic Hepatitis B Virus Mid-Stage Products (Phase-II)
8. Chronic Hepatitis B Virus Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chronic Hepatitis B Virus Discontinued Products
13. Chronic Hepatitis B Virus Product Profiles
14. Key Companies in the Chronic Hepatitis B Virus Market
15. Key Products in the Chronic Hepatitis B Virus Therapeutics Segment
16. Dormant and Discontinued Products
17. Chronic Hepatitis B Virus Unmet Needs
18. Chronic Hepatitis B Virus Future Perspectives
19. Chronic Hepatitis B Virus Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Get a Detailed Assessment into the Ongoing Clinical and Regulatory Development Activities, at: Chronic Hepatitis B Virus Therapeutic Outlook
Contact Info:
Shruti Thakur
Manager (Marketing and Branding)
Email: info@delveinsight.com
https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.